Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...

A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer. This is an ASCO Meeting ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

This Canadian study included 111 women (median age 63 years), most of whom (90%, n=100) had invasive ductal carcinoma. Over the entire cohort, more than half (54%, n=60) underwent mastectomy and 46% ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Sentinel lymph node (SLN) resection has been advocated as an option to reduce morbidity for women undergoing surgery for breast cancer. When the sentinel node is negative for breast cancer, SLN ...

Please provide your email address to receive an email when new articles are posted on . Patients with breast cancer had similar survival whether they underwent completion axillary lymph node ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...